Engineered immune cells take on Hard-to-Treat ovarian and endometrial cancers
NCT ID NCT07664735
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a one-time treatment called OPB-201, where a patient's own immune cells are modified in a lab to better recognize and attack cancer cells that carry a protein called PRAME. The study will enroll 30 adults with recurrent endometrial cancer or platinum-resistant ovarian cancer. The main goals are to check if the treatment is safe and to find the best dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- OPB-201 (a personalized T cell therapy that targets PRAME, a protein found on cancer cells)
- What this could lead to
- If successful, this could lead to a new treatment option for people with recurrent endometrial or platinum-resistant ovarian cancer who have few alternatives.
- What could go wrong
- This is an early Phase 1 trial with only 30 participants, so safety and the right dose are still being figured out. The therapy may not shrink tumors or could cause serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- What raises endometrial cancer risk in black women? a study digs in
- Can a new PET tracer light up hidden cancers?
- A Two-for-One surgery: could tube removal during Weight-Loss surgery slash ovarian cancer risk?
- Can AI spot ovarian cancer on CT scans before It's too late?
- Can Lab-Grown tumors unlock the secrets of ovarian cancer resistance?